Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Complement activation plays a key role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). While eculizumab effectively prevents relapses, its role in acute attacks remains uncertain. Methods: We retrospectively analyzed 38 patients with acute NMOSD treated with eculizumab across seven tertiary hospitals in China. Neurological assessments included EDSS, visual, motor, and sensory deficits, evaluated at baseline and weekly through 8 weeks.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
